HC Wainwright Issues Optimistic Outlook for RIGL Earnings

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) - Analysts at HC Wainwright upped their Q3 2025 earnings per share estimates for shares of Rigel Pharmaceuticals in a research report issued on Wednesday, May 7th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will earn $0.38 per share for the quarter, up from their prior forecast of $0.34. HC Wainwright has a "Buy" rating and a $57.00 price target on the stock. The consensus estimate for Rigel Pharmaceuticals' current full-year earnings is $0.22 per share. HC Wainwright also issued estimates for Rigel Pharmaceuticals' Q4 2025 earnings at $0.45 EPS.

RIGL has been the subject of a number of other research reports. Citigroup boosted their price objective on Rigel Pharmaceuticals from $49.00 to $55.00 and gave the stock a "buy" rating in a report on Thursday, March 6th. Cantor Fitzgerald increased their price objective on shares of Rigel Pharmaceuticals from $20.00 to $23.00 and gave the stock a "neutral" rating in a research report on Wednesday, May 7th. B. Riley upped their target price on shares of Rigel Pharmaceuticals from $20.00 to $24.00 and gave the stock a "neutral" rating in a report on Wednesday, March 5th. Finally, StockNews.com downgraded shares of Rigel Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, March 8th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $36.40.

Rigel Pharmaceuticals Price Performance

Shares of RIGL traded down $0.18 during midday trading on Thursday, hitting $18.43. The stock had a trading volume of 104,364 shares, compared to its average volume of 212,314. The company has a 50 day simple moving average of $18.53 and a two-hundred day simple moving average of $19.89. The firm has a market cap of $329.29 million, a price-to-earnings ratio of 131.65 and a beta of 1.34. Rigel Pharmaceuticals has a twelve month low of $7.48 and a twelve month high of $29.82.

Rigel Pharmaceuticals (NASDAQ:RIGL - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.14 by $0.49. Rigel Pharmaceuticals had a negative return on equity of 14.80% and a net margin of 2.46%. The business had revenue of $53.33 million for the quarter, compared to the consensus estimate of $43.87 million. During the same quarter last year, the business posted ($0.50) EPS.

Institutional Investors Weigh In On Rigel Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC grew its stake in Rigel Pharmaceuticals by 158.6% during the third quarter. Barclays PLC now owns 27,345 shares of the biotechnology company's stock valued at $442,000 after acquiring an additional 16,772 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Rigel Pharmaceuticals by 45.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 26,238 shares of the biotechnology company's stock valued at $425,000 after purchasing an additional 8,140 shares in the last quarter. SG Americas Securities LLC raised its stake in shares of Rigel Pharmaceuticals by 42.8% during the 4th quarter. SG Americas Securities LLC now owns 9,429 shares of the biotechnology company's stock worth $159,000 after acquiring an additional 2,827 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in shares of Rigel Pharmaceuticals in the 4th quarter valued at approximately $63,000. Finally, Rhumbline Advisers grew its position in Rigel Pharmaceuticals by 6.3% during the 4th quarter. Rhumbline Advisers now owns 25,143 shares of the biotechnology company's stock worth $423,000 after purchasing an additional 1,485 shares during the last quarter. Hedge funds and other institutional investors own 66.23% of the company's stock.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.